Widely Prescribed Thyroid Hormone Could Prevent Pediatric Brain Tumor Recurrence
A research team investigating children’s brain tumors has found promising results combining a hormone treatment with standard chemotherapy protocols. Triiodothyronine, commonly called T3, is a medication long used to manage thyroid disorders in patients throughout the lifespan. The hormone showed enhanced effectiveness when added to conventional cancer therapy in laboratory studies and animal models.
A clinical trial is now recruiting pediatric patients to test whether this combined approach works in actual clinical settings.
Medulloblastoma accounts for the leading category of malignant pediatric brain cancers, striking hundreds of young children annually. Treatment currently requires aggressive intervention that combines surgical removal with systemic therapy and radiation. Nevertheless, tumor recurrence occurs in roughly 30% of cases despite these intensive approaches.
Researcher Zeng-jie Yang from Fox Chase’s Cancer Epigenetics Institute explained that standard chemotherapy destroys cancer by targeting cells that divide rapidly. The problem: healthy cells also divide rapidly, meaning chemotherapy damages normal tissue alongside cancer cells, creating serious side effects.
The study examined differentiation therapy as an alternative mechanism for slowing cancer progression. This strategy encourages tumor cells to mature rather than attempting direct cellular elimination. Once cells reach maturity, they stop multiplying and lose malignant characteristics.
T3 stimulates this transformation in medulloblastoma cells, pushing them toward normal development patterns. Once differentiation occurs successfully, the cells become unable to fuel cancer growth or cause relapse events.
Laboratory experiments and mouse studies examined combining both treatment modalities simultaneously. Adding T3 after chemotherapy proved more effective at suppressing growth than using chemotherapy exclusively and allowed researchers to reduce chemotherapy doses while achieving identical tumor control.
Tumors stopped returning after the combined treatment concluded. Additionally, T3 worked against chemotherapy-resistant cancer cells, suggesting utility across different patient subtypes. Safety investigation was critical given the pediatric patient population affected by this cancer type.
While T3 has been given to patients across diverse age groups safely for many decades, very high doses can cause temporary heart rate elevation in some patients. Testing showed T3 produced mild and brief heart rate changes that responded well to propranolol management. Importantly, propranolol did not reduce the hormone’s anti-cancer abilities or create additional problems.
The advantages presented by this research support rapid advancement toward human testing in clinical settings quickly. T3 carries existing FDA approval for other medical conditions nationwide and its manufacturing costs are low relative to newer cancer therapies in development.
A pediatric clinical trial has already started with involvement from the Pediatric Neuro-Oncology Consortium which connects multiple children’s hospitals across the nation for coordinated research efforts. The trial’s success could substantially boost survival outcomes for pediatric cancer patients while decreasing side effects from conventional treatments.
The fight against pediatric brain tumors has attracted plenty of research attention, and companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are leveraging the insights they get in studying these cancers to develop treatments that promise to change the prognosis of patients.
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer
A research team investigating children’s brain tumors has found promising results combining a hormone treatment with standard chemotherapy protocols. Triiodothyronine, commonly called T3, is a medication long used to manage thyroid disorders in patients throughout the lifespan. The hormone showed enhanced effectiveness when added to conventional cancer therapy in laboratory studies and animal models.
A clinical trial is now recruiting pediatric patients to test whether this combined approach works in actual clinical settings.
Medulloblastoma accounts for the leading category of malignant pediatric brain cancers, striking hundreds of young children annually. Treatment currently requires aggressive intervention that combines surgical removal with systemic therapy and radiation. Nevertheless, tumor recurrence occurs in roughly 30% of cases despite these intensive approaches.
Researcher Zeng-jie Yang from Fox Chase’s Cancer Epigenetics Institute explained that standard chemotherapy destroys cancer by targeting cells that divide rapidly. The problem: healthy cells also divide rapidly, meaning chemotherapy damages normal tissue alongside cancer cells, creating serious side effects.
The study examined differentiation therapy as an alternative mechanism for slowing cancer progression. This strategy encourages tumor cells to mature rather than attempting direct cellular elimination. Once cells reach maturity, they stop multiplying and lose malignant characteristics.
T3 stimulates this transformation in medulloblastoma cells, pushing them toward normal development patterns. Once differentiation occurs successfully, the cells become unable to fuel cancer growth or cause relapse events.
Laboratory experiments and mouse studies examined combining both treatment modalities simultaneously. Adding T3 after chemotherapy proved more effective at suppressing growth than using chemotherapy exclusively and allowed researchers to reduce chemotherapy doses while achieving identical tumor control.
Tumors stopped returning after the combined treatment concluded. Additionally, T3 worked against chemotherapy-resistant cancer cells, suggesting utility across different patient subtypes. Safety investigation was critical given the pediatric patient population affected by this cancer type.
While T3 has been given to patients across diverse age groups safely for many decades, very high doses can cause temporary heart rate elevation in some patients. Testing showed T3 produced mild and brief heart rate changes that responded well to propranolol management. Importantly, propranolol did not reduce the hormone’s anti-cancer abilities or create additional problems.
The advantages presented by this research support rapid advancement toward human testing in clinical settings quickly. T3 carries existing FDA approval for other medical conditions nationwide and its manufacturing costs are low relative to newer cancer therapies in development.
A pediatric clinical trial has already started with involvement from the Pediatric Neuro-Oncology Consortium which connects multiple children’s hospitals across the nation for coordinated research efforts. The trial’s success could substantially boost survival outcomes for pediatric cancer patients while decreasing side effects from conventional treatments.
The fight against pediatric brain tumors has attracted plenty of research attention, and companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are leveraging the insights they get in studying these cancers to develop treatments that promise to change the prognosis of patients.
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer
